Analysis of extracellular vesicles using magnetic nanoparticles in blood of patients with acute coronary syndrome

• Published in: Biochemistry (Moscow) 2016-04, Vol.81 (4), p.382-391
• Main Authors: Vagida, M. S., Arakelyan, A., Lebedeva, A. M., Grivel, J. Ch, Shpektor, A. V., Vasilieva, E. Yu, Margolis, L. B.
• Format: Article
• Language: English
• Subjects: Acute coronary syndrome; Acute Coronary Syndrome - blood; Acute Coronary Syndrome - diagnosis; Aged; Antibodies - chemistry; Antibodies - immunology; Biochemistry; Biomedical and Life Sciences; Biomedicine; Bioorganic Chemistry; Blood; Blood platelets; Blood Platelets - metabolism; Cardiovascular disease; Cardiovascular diseases; Case-Control Studies; Extracellular matrix; Extracellular Vesicles - chemistry; Extracellular Vesicles - metabolism; Female; Flow Cytometry; Health aspects; Histocompatibility Antigens Class I - metabolism; Humans; Integrin alpha2 - immunology; Integrin alpha2 - metabolism; Life Sciences; Magnetite Nanoparticles - chemistry; Male; Medical examination; Microbiology; Middle Aged; Myocardial infarction; Nanoparticles; Physiological aspects; Platelet Endothelial Cell Adhesion Molecule-1 - immunology; Platelet Endothelial Cell Adhesion Molecule-1 - metabolism
• ISSN: 0006-2979; 1608-3040
• DOI: 10.1134/S0006297916040088

Extracellular vesicles (EVs) are released from various cell types and play an important role in intercellular interactions. In our study, we investigated abundance of individual EVs in patients with acute forms of ischemic heart disease. Previously, we developed an approach for individual analysis of EVs conjugated with magnetic nanoparticles (MNPs), which was applied in the current study for analyzing phenotypic composition of EVs (by staining for markers CD31, CD41a, and CD63). EVs were isolated using fluorescently labeled MNPs containing anti-CD31, CD41a, or CD63 antibodies and analyzed by combining fluorescently labeled anti-CD41a and CD63, CD31 and CD63, or CD41a and CD31 antibodies, respectively. EVs were analyzed in 30 individuals: 17 healthy volunteers and 13 patients with acute coronary syndrome (ACS). Six and seven ACS patients were with acute myocardial infarction and unstable angina, respectively. It was found that patients with ACS and healthy volunteers contained a dominant subset of EVs expressing surface CD41a antigen, suggesting that they originated from platelets. In addition, the total number of EVs isolated using either of the surface markers examined in our study was higher in patients with ACS compared to healthy volunteers. The subgroup of patients with acute myocardial infarction was found to contain significantly higher number of blood EVs compared to the control group. Moreover, increased number of EVs in patients with ACS is mainly due to the increased number of EVs in the subset of EVs bearing CD41a. By analyzing individual EVs, we found that plasma of patients with ACS, particularly upon developing of myocardial infarction, contained dominant platelet-derived EVs fraction, which may reflect activation of platelets in such patients.